Fig. 6

Spectral analysis of nociceptive firing in control conditions and the presence of CIM0216. (A, B) Example traces of MUA within one experiment in the control condition and during 5 μM CIM0216 in females (A) and males (B). Notice, there is only a single spike in the control condition in both males and females, while during the 2-min active phase of 5 μM CIM0216 application, the number of spikes increased differently for females and males, within the initial 0.5-s of drug application. (C, D) Spectrograms show the average interspike intervals (ISI) for all experiments in females (C) in the control conditions (grey line, n = 13), after application of 50 μM PregS (blue line, n = 7) and after 5 μM CIM0216 application (red line, n = 6) and in males (D) in the control condition (grey line, n = 11), after application of 50 μM PregS (blue line, n = 5) and after 5 μM CIM0216 application (red line, n = 6) on panel. The dotted vertical line at 0.1 ISI indicates the 10 Hz frequency. The number of ISIs below 0.1 s (i.e. reflecting spiking activity above 10 Hz frequency) is higher in females after 50 μM PregS and 5 μM CIM0216. (E, F) Distribution of fibres (clusters) according to the firing frequency in the control condition (top panel; grey) and after application of 5 μM CIM0216 (bottom panel; red) presented as mean ± SEM for females (E) (n = 6) and males (F) (n = 6) on panel (F). Notice that 5 μM CIM0216 induced nociceptive firing with θ-range of spiking activity for both sexes, whereas in females, θ-range, as well as higher spiking activity of α and β-ranges, were induced